



Supernus Pharmaceuticals, Inc.
Investor Relations Department
1550 East Gude Drive
Rockville, MD 20850
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: SUPN

| | |
|---------------|----------------------------|
| Last Trade: | 43.95 |
| Trade Time: | 4:00 PM ET Aug 21, 2017 |
| Change: | 0.75 (+1.736%) |
| Day Range | 43.25 - 44.13 |
| 52-Week Range | 17.25 - 46.45 |
| Volume | 445,777 |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Supernus Pharmaceuticals extensive expertise in product development has been built over the past 20 years: initially as a standalone development organization, then as a U.S. subsidiary of Shire plc and, upon our acquisition of substantially all the assets of Shire Laboratories Inc. in late 2005, as Supernus Pharmaceuticals.

... [\(more\)](#)

Stock Information



Press Releases [\[View all \]](#)

- Aug 15, 2017*
[Supernus Defeats Second Generic Challenger to Oxtellar XR®](#)
- Aug 2, 2017*
[Supernus Announces Record Second Quarter 2017 Financial Results](#)
- Jul 19, 2017*
[Supernus to Host Second Quarter 2017 Earnings Conference Call](#)
- Jun 21, 2017*
[Supernus Announces that its Partner Shire Receives FDA Approval for Mydayis™ for ADHD](#)
- Jun 1, 2017*
[Supernus to Present at Jefferies Healthcare Conference](#)

Financials & Filings [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 16, 2017*
[Annual Report \(10-K\)](#)
- Apr 27, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 3, 2017*
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Jan 20, 2017*
[Quarterly Report \(10-Q\)](#)